Phase 2 N=16 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) Response — 14 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=131 Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
Rheumatoid Arthritis
Primary: Percentage of Subjects Reporting At Least One Treatment-emergent Adverse Event (TEAE) During The Study Period — 70.8 percentage of participants
Phase 2 N=169 Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C
Hepatitis C, Chronic
Primary: Relapse Rate — 30.5; 37.7; 35.1 percentage of participants — p=0.72
Phase 3 N=592 Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: PASI 75 at Week 12 — 48.3; 65.2 Percentage of participants — p=<0.001
Phase 4 N=140 Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up
Non ST Elevation Myocardial Infarction
Primary: Major Adverse Cardiac and Cerebrovascular Events (MACCE) — 35.3; 13.8 Percentage of study group
Phase 3 N=311 A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density
Low Bone Mineral Density · Osteopenia · Osteoporosis
Primary: Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 6 — 0; 0 Participants
N/A N=1,754 Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Primary: Number of Participants With American College of Rheumatology (ACR) Criteria — 194; 1316; 179; 1133 participants — p=0.010
Phase 2 N=311 Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295)
Asthma · Common Cold · Picornavirus Infection
Primary: Percentage of Participants With Rhinovirus PCR-Positive Colds — 2.6; 2.5 percentage of participants — p=0.973
N/A N=10 Does Adding Milk to Tea Delay Gastric Emptying?
Gastric Emptying
Primary: Tmax — 38; 30 minutes
N/A N=302 Adult Normative Performance of the Quotient ADHD System
ADHD
Primary: Well-screened, Non-ADHD Controls to Augment the Existing Adolescent and Adult Database Thus Expanding the Normative Reference Range of Performance of the Quotient®…
Phase 2 N=20 A Phase 2 Study Of PF-00232798 In HIV Positive Patients
HIV
Primary: Change From Baseline in Log 10-transformed Human Immunodeficiency Virus (HIV) Viral Load at Day 11 — 4.692; 4.338; 4.306; 4.483 log10 copies/mL
Phase 3 N=1,198 Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)
Neuromuscular Blockade · Arthroplasty, Replacement, Hip · Arthroplasty, Replacement, Knee
Primary: Number of Participants With One or More Adjudicated Events of Bleeding (Major or Non-major) With Onset Within 24 Hours After Study Drug Administration — 17; 24…
Phase 4 N=22 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients
Hypertension · Brain Tumor · Epilepsy
Primary: The Primary Endpoint of This Trial is the Proportion of Patients Who Did Not Require Rescue Antihypertensive Medication to Maintain SBP Below 130 mmHg (i.e. Clevidipine…
Phase 2 N=59 Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
Acute Myeloid Leukemia
Primary: Overall Response: Number of Participants With Complete Remission or Complete Remission Without Platelet Recovery — 42; 3 participants
N/A N=25 The Role of Oxidative Stress in the Cardiovascular Consequences of Sleep Apnea
Sleep Apnea
Primary: Flow Mediated Dilation — 5.7; 9.5; 7.3 percentage change of vessel diamter — p=0.02